To summarize the influence of pre-existing diabetes on mortality and morbidity in men with prostate cancer. We searched MEDLINE and EMBASE from inception through 1 October 2008. Search terms were related to diabetes, cancer and prognosis. Studies were included if they reported an original data analysis of prostate cancer prognosis, compared outcomes between men with and without diabetes and were in English. Titles, abstracts and articles were reviewed independently by two authors. Conflicts were settled by consensus or third review. We abstracted data on study design, analytic methods, outcomes and quality. We summarized mortality and morbidity outcomes qualitatively and conducted a preliminary meta-analysis to quantify the risk of long-term (43 months), overall mortality. In total, 11 articles were included in the review. Overall, one of four studies found increased prostate cancer mortality, one of two studies found increased nonprostate cancer mortality and one study found increased 30-day mortality. Data from four studies could be included in a preliminary meta-analysis for long-term, overall mortality and produced a pooled hazard ratio of 1.57 (95% CI: 1.12-2.20). Diabetes was also associated with receiving radiation therapy, complication rates, recurrence and treatment failure. Our analysis suggests that preexisting diabetes affects the treatment and outcomes of men with prostate cancer.
Introduction
The American Cancer Society estimates that, in 2009, there will be 192 280 new cases of prostate cancer in the United States, 1 and approximately 63% of those cases will be diagnosed in men aged 65 years or older. 2 As prostate cancer tends to affect older men, such patients are likely to have other comorbid conditions. In fact, about 62% of people aged 65 and older have two or more chronic conditions. 3 One of the most common chronic conditions in older adults is diabetes. An estimated 23.6 million people in the United States have diabetes mellitus, representing approximately 8% of the adult population. 4 Diabetes rates in the population older than 65 years are even higher, an estimated 15.3%. 5 A recent meta-analysis found that pre-existing diabetes was associated with worse overall, long-term mortality in cancer patients generally. 6 However, the impact of diabetes varied across different cancer types (ranging from 1.09 for pancreas to 1.76 for endometrial), suggesting the need to evaluate specific cancers individually. One reason that prostate cancer warrants particular attention is that a meta-analysis by Kasper and Giovannucci 7 showed a decreased risk of incident prostate cancer among men with diabetes (pooled relative risk: 0.84; 95% confidence interval (CI): 0.76-0.93), raising the question of whether this protective effect extends to prognosis among men who do get prostate cancer. However, little research has been conducted in this area. Diabetes could have important implications for treatment selection and outcome in prostate cancer patients, but no systematic reviews have been conducted to test how pre-existing diabetes affects mortality and other important outcomes. Owing to the indolent nature of prostate cancer and the long-term expected survival associated with it, attention to modifiable conditions like diabetes and its potential influence on morbidity and mortality is warranted.
We conducted a systematic literature review to summarize and synthesize the impact of diabetes on prostate cancer management and prognosis. We also wanted to quantify the impact of pre-existing diabetes on prostate cancer-specific and overall mortality. Although there was insufficient evidence to conduct a formal metaanalysis of prostate cancer-specific mortality, we were able to conduct a preliminary assessment of the impact of diabetes on overall, long-term mortality.
Material and methods

Objectives
This systematic review and meta-analysis was conducted to summarize and quantify the effect of pre-existing diabetes on mortality among prostate cancer patients. We also examined and summarized the impact of preexisting diabetes on nonmortality outcomes.
Literature search
We searched the MEDLINE and EMBASE databases from inception to 1 October 2008 to identify articles that addressed the relationship between pre-existing diabetes and cancer prognosis. Search terms were related to diabetes (for example, diabetes, glucose intolerance and hyperglycemia), cancer (for example, cancer and malignant neoplasm) and prognosis (for example, mortality, survival and recurrence). Articles were limited to English language, human studies. We also reviewed the reference lists of included articles to identify any other studies that were not captured through the initial literature search.
To be included in this review, articles had to (1) evaluate prognosis by glycemic status, (2) include patients with prostate cancer and (3) contain an original data analysis. Articles were excluded if the study (1) included noncancer patients, (2) included only subjects with diabetes, (3) did not analyze a prognostic outcome, (4) was a case report or (5) was not in English. To evaluate the studies' eligibility for inclusion, titles, abstracts and articles were reviewed independently by two authors; discrepancies were resolved by a third reviewer or by consensus. To be included in the metaanalysis, the articles had to provide a risk estimate (for example, hazard ratio and relative risk) and a measure of precision (for example, confidence interval) for the impact of pre-existing diabetes on overall, long-term (43 months) mortality. Authors of articles that only reported that diabetes was 'not significant' were contacted to obtain the actual estimates and precision measures.
Data abstraction and analysis
The following data were abstracted from included articles: sample size, data source, study recruitment years, study eligibility criteria, length of follow-up, outcome assessed, risk estimate and confounders adjusted for in models. All studies were evaluated for quality based on population source, method of diabetes and outcome ascertainment, and statistical methods. Each article was abstracted by one author, and a second author reviewed the abstraction for accuracy.
We summarized qualitatively the impact of diabetes on prostate cancer-specific mortality, nonprostate cancer mortality, overall mortality and other mortality outcomes. We also summarized the influence of diabetes on nonmortality outcomes. There was sufficient data to conduct a preliminary meta-analysis for overall, longterm mortality by diabetes status but not the other outcomes. On the basis of the Q-statistic (12.76 on 3 degrees of freedom, P ¼ 0.005) and I 2 of 76.5%, we determined that there was substantial between-study heterogeneity and therefore used a DerSimonian-Laird random-effects model for the meta-analysis. Begg's (P40.99) and Egger's (P ¼ 0.43) tests did not find evidence of publication bias. However, we conducted a sensitivity analysis using Duval and Tweedie's 8 nonparametric 'trim and fill' to assess the effect of hypothetical missing studies, as we were unable to include two nonsignificant studies with insufficient reporting. Figure 1 illustrates the steps in the evaluation of the articles for inclusion in the review and meta-analysis. The literature search identified 8208 titles, of which 7473 were excluded, leaving 735 abstracts. There were 486 abstracts that did not meet our eligibility criteria and were excluded, leaving 249 articles for further review. On the basis of the review of the 249 articles, 97 provided some estimate of the impact of diabetes on cancer prognosis, and 4 additional articles were identified by searching references. Of the 101 articles, 11 [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] addressed the impact of diabetes on prostate cancer in particular and were included in this review. The article by Merrick et al. 15 reports an expansion and extension of a previous publication. 14 
Results
Literature search
Study description and quality assessment
The majority of the studies were conducted in the United States (n ¼ 7). 9, 10, [13] [14] [15] 17, 19 The other four studies were conducted in Korea, 16 Germany, 11 Sweden 12 and the Netherlands. 18 All of the studies were published within the past 10 years: two studies in 1999, 13, 19 17 The sample sizes ranged from 256 16 to 13 398. 19 The four studies included in the meta-analysis were all deemed high quality by our review. [15] [16] [17] [18] Two were population-based cohorts 16, 18 and two were groups of patients undergoing radiation therapy. 15, 17 All four studies used blood test or medical records to ascertain diabetes. Two studies used national registries, 16, 18 one used medical records 15 and one used active study followup 17 to determine vital status. Each study used adjusted Cox proportional hazards models. Though all of the studies adjusted for age, other covariates varied across studies (see Table 1 ). Of the remaining seven studies included in the review, six used medical records to ascertain diabetes status, [10] [11] [12] [13] [14] 19 and one used selfreport. 9 Three used national registries to determine vital status, 10, 12, 19 one used active follow-up 9 and the remaining three used medical records. 11, 13, 14 Though outcomes varied, all studies used more sophisticated statistical methods with regression models.
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Diabetes and mortality
Of the 11 studies included in the systematic review, 4 assessed prostate cancer-specific mortality, 2 assessed nonprostate cancer mortality, 1 assessed 30-day mortality and 6 assessed overall, long-term mortality (Tables 1 and  2 ). Hammarsten and Hogstedt 12 was the only study to find an elevated risk of prostate cancer-specific mortality among men with type 2 diabetes (estimate not reported; P ¼ 0.035). They examined 320 men who were seen in the Urological Section at a Swedish hospital between 1995 and 2002. Three other studies that evaluated prostate cancer-specific mortality did not find statistically significant relationships. Merrick et al. 15 investigated prostate cancer-specific mortality among 530 men who had undergone brachytherapy at least 3 years before but did not find a significant relationship in univariate analyses (P ¼ 0.712), therefore diabetes was not included in the multivariate analyses. Smith et al. 17 evaluated 1551 men with prostate cancer participating in a randomized controlled trial of radiation therapy with short-versus long-term adjuvant goserelin for locally advanced prostate cancer. In its evaluation of prostate cancerspecific mortality, they found a hazard ratio of 0.80 (95% CI: 0.51-1.25; P ¼ 0.32). Froehner et al. 11 reported only that diabetes was not significantly associated with prostate cancer mortality.
Similarly, Froehner et al.
11 evaluated noncancer mortality but again reported only that diabetes was not significant. In contrast, Smith et al. 17 did find a significant association between diabetes and nonprostate cancer mortality (hazard ratio: 2.12; 95% CI: 1.69-2.66; Po0.0001). Wilt et al. 19 examined the 30-day mortality outcomes for 13 398 men in the Veterans Administration database who underwent radical prostatectomy between 1986 and 1996. They found that pre-existing diabetes was associated with increased odds of 30-day mortality (odds ratio: 1.87; 95% CI: 1.11-3.15; P ¼ 0.02), after adjusting for a number of factors. Thus, one of four studies found increased prostate cancer-specific mortality, one of two studies found increased nonprostate cancer mortality, and one study found increased 30-day mortality.
A total of six studies reported on the impact of preexisting diabetes on overall, long-term mortality (Table 1). 10 10, 11 We attempted to contact these authors, but they were either unable to provide the needed estimates or did not respond. Combining the hazard ratios from the four studies with sufficient reporting in a random-effects model produced a pooled hazard ratio of 1.57 (95% CI: 1.12-2.20; P ¼ 0.008) (Figure 2) . In a sensitivity analysis using the nonparametric trim and fill method, which adjusts for publication bias, the pooled hazard ratio was attenuated but remained statistically significant with a hazard ratio of 1.47 (95% CI: 1.08-2.00; P ¼ 0.015).
Diabetes and nonmortality outcomes
A total of five studies examined the impact of preexisting diabetes on a variety of nonmortality outcomes, including treatment choice, complications and acute morbidities, treatment failure and recurrence. 9, 13, 14, 15, 18 Two studies found that diabetes affected treatment choice.
9,18 Specifically, among prostate cancer patients aged 35 to 64, men with diabetes were more likely to receive treatment with radiotherapy versus men without diabetes (odds ratio: 2.24; 95% CI: 1.29-3.87), although no differences were found between men with and without diabetes for surgery or hormonal therapy and no differences were found for men aged 65 and older. 18 Similarly, Chan et al. 9 found that compared with surgery, men with diabetes were more likely to undergo external beam radiation (OR: 1.54; 95% CI: 1.12-2.13) or hormonal therapy (OR: 1.63; 95% CI: 1.17-2.27), but they found no difference in brachytherapy or watchful waiting.
Herold et al. 13 found no difference in acute morbidities between men with and without diabetes receiving radiotherapy, but they did find differences in late complications. There was a higher 5-year actuarial rate of combined Grades 2-4 gastrointestinal and genitourinary late complications for men with versus without diabetes (34 versus 23%, P ¼ 0.013).
In both the original Merrick study and its extension, there was no association between diabetes and biochemical progression-free survival. 14, 15 In terms of cancer recurrence, Chan et al. 9 found no association in an overall analysis by diabetes status for patients undergoing surgery or radiation therapy; however, among patients undergoing radiation therapy stratified by prognostic risk, patients in the low-risk group who were diabetic were more likely to recur (hazard ratio: 3.79; 95% CI: 1.28-11.19; P ¼ 0.01). In addition, among men who underwent radiation therapy and who were aged 69 years or younger at diagnosis, diabetic status was associated with reduced time to treatment failure (hazard ratio ¼ 2.17; 95% CI: 1.02-4.62, P ¼ 0.04). 9 
Discussion
Diabetes and prostate cancer are both prevalent conditions in older men; however, little research has been Two studies assessed diabetes and overall mortality but only reported that diabetes was not significant (Fleming et al.
10
; Froehner et al.
11
).
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Diabetes and prostate cancer prognosis CF Snyder et al conducted to evaluate the impact of pre-existing diabetes on prostate cancer treatment and outcomes. We conducted a systematic review to summarize the research to date on how diabetes affects prostate cancer mortality and morbidity. We also conducted a preliminary metaanalysis to quantify the effects of diabetes on long-term, overall mortality. Although only four studies could be included in this meta-analysis, resulting in a pooled hazard ratio of 1.57 (95% CI: 1.12-2.20), perhaps of greater importance is the lack of evidence to conduct even a preliminary meta-analysis of the impact of diabetes on prostate cancer-specific mortality. As diabetes is associated with worse mortality in general (aside from any cancer diagnosis), it is particularly important to investigate the influence diabetes on prostate cancerspecific outcomes, and future research should focus on this area. Studies conducted to date indicate mixed results regarding the impact of diabetes on prostate cancer-specific and nonprostate cancer mortality. Additional research is critical to inform our understanding of whether the difference found in overall mortality is cancer-related, noncancer related or both. Diabetes was also associated with differences in treatment selection, complications and recurrence. What might explain an adverse biological interaction between diabetes mellitus and prostate cancer? As discussed in our previous paper, 6 an environment of hyperinsulinemia and hyperglycemia might lead to increased tumor proliferation and metastasis. In vitro, insulin seems to be a growth factor for prostatic epithelia. 20 Insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 are also associated with prostate growth. 21, 22 Such findings have prompted the development of IGF receptor inhibitors, and prostate cancer has been cited as a tumor type that may benefit from treatment with such agents. Studies are underway to elucidate further the biology of diabetes mellitus, IGF and prostate cancer.
There might also be biological interactions with regards to the effects of radiotherapy. Chan et al. 9 found that younger men with diabetes who received radiotherapy had a shorter time to treatment failure. Herold et al. 13 found that men with diabetes who underwent radiotherapy had higher rates of gastrointestinal and genitourinary late complications than men without diabetes. Potential biological mechanisms for these worse outcomes among men with diabetes include alterations in IGF, its receptors and their signaling pathways that may affect resistance to treatment. 23 For example, heme oxygenase-1 and clusterin are upregulated in diabetes mellitus and associated with worse treatment outcomes. 24, 25 There are at least two additional circumstances in which prostate cancer therapy can adversely interact with pre-existing diabetes. First, androgen-deprivation therapy initiation might aggravate insulin resistance and provoke deterioration in glycemia and/or dyslipidemia. Second, use of corticosteroids (for example, in combination with docetaxel) can immediately aggravate glycemia and heighten diabetes-related susceptibility to bacterial infection. Further research should explore the biological mechanisms for differences in treatment outcomes and evaluate whether differences in outcomes are related to selection bias or are related to the treatment itself.
This study benefits from rigorous methods, including a comprehensive, systematic review of the literature. The study team included experts in multiple disciplines, including cancer, diabetes and epidemiology. All steps of the process involved two levels of review with disagreements addressed by consensus or a third review. Nevertheless, there are some limitations to our study that warrant mention. One challenge was the heterogeneity of studies in terms of the populations included and the outcomes assessed. For the four studies included in the meta-analysis, each used adjusted multivariate Cox proportional hazards models, and we allowed for between-study differences by using a random-effects model. However, two of the studies used populationbased cohorts, whereas two studies used cohorts undergoing radiation therapy, therefore these results should be interpreted with caution. Though we do not know the direction of effect in the two studies we were unable to include due to insufficient reporting, we are reassured by the consistent result of our sensitivity analysis. Variation in study design and other quality components across the 11 studies included in the systematic review may limit conclusions.
Perhaps the most important finding from this review is the lack of research investigating how diabetes affects prostate cancer prognosis. As noted above, only 11 studies addressed this issue. Overall, 6 of those 11 studies estimated the impact of diabetes on overall, longterm mortality, but only four studies addressed the more important question of whether diabetes affects prostate 
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